Risperidone

Generic Name: Risperidone

Brand Names: Perseris, Risperdal, Rykindo, Uzedy, Okedi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 106266-06-2

Unique Ingredient Identifier: L6UH7ZF8HC

Background: Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication: Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions: Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state

Associated Therapies: -

Clinical Trials

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

Completed

Conditions: Psychosis
Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Risperidone

First Posted Date: 2014-01-13

Last Posted Date: 2019-01-22

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 134

Registration Number: NCT02034253

Locations: 🇺🇸
Sparks Center, Birmingham, Alabama, United States

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia

Interventions: Drug: risperidone
Drug: Sertindole

First Posted Date: 2013-12-27

Last Posted Date: 2020-03-26

Lead Sponsor: Birte Glenthoj

Target Recruit Count: 1

Registration Number: NCT02021201

Locations: 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Other: Placebo
Drug: RO5545965
Drug: risperidone

First Posted Date: 2013-12-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT02019329

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Valproate
Drug: Lithium
Other: Placebo
Drug: Risperidone
Drug: Olanzapine

First Posted Date: 2013-11-06

Last Posted Date: 2015-11-20

Lead Sponsor: University of British Columbia

Target Recruit Count: 159

Registration Number: NCT01977300

Locations: 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

Not Applicable

Completed

Conditions: Imaging of the Brain and Antipsychotics
Neuronal Network Changes

Interventions: Drug: Risperidone
Other: Placebo

First Posted Date: 2013-08-29

Last Posted Date: 2018-04-30

Lead Sponsor: Northwell Health

Target Recruit Count: 11

Registration Number: NCT01931059

Locations: 🇺🇸
Zucker-Hillside Hospital, Glen Oaks, New York, United States

Antipsychotic Effects on Brain Function in Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder

Interventions: Drug: Aripiprazole
Drug: Risperidone
Drug: Modafinil

First Posted Date: 2013-08-01

Last Posted Date: 2020-04-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 4

Registration Number: NCT01913327

Locations: 🇺🇸
University of California, San Francisco, California, United States

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

Terminated

Conditions: Schizophrenia

Interventions: Drug: Oral atypical anti-psychotic
Drug: Risperidone

First Posted Date: 2013-07-10

Last Posted Date: 2014-05-08

Lead Sponsor: Xian-Janssen Pharmaceutical Ltd.

Target Recruit Count: 640

Registration Number: NCT01894984

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

Not Applicable

Completed

Conditions: Psychotic Disorder Not Otherwise Specified
Schizoaffective Disorder
Severe Bipolar Disorder With Psychotic Features
Schizophrenia

Interventions: Drug: risperidone

First Posted Date: 2013-06-17

Last Posted Date: 2018-08-27

Lead Sponsor: Northwell Health

Target Recruit Count: 88

Registration Number: NCT01878513

Locations: 🇺🇸
Zucker Hillside Hospital, Glen Oaks, New York, United States

An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

Phase 4

Completed

Conditions: Schizophrenia
Schizophreniform Disorder
Schizoaffective Disorder

Interventions: Drug: Risperidone

First Posted Date: 2013-05-16

Last Posted Date: 2013-08-14

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 80

Registration Number: NCT01855074

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy